Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product

BioDrugs

Volumn 24, Issue 6, 2010, Pages 347-357

  Srgel, Fritz ^a,b   Lerch, Helmut ^c   Lauber, Thomas ^c  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Biological products; Filgrastim; General

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; ZARZIO;

ANIMAL CELL; ARTICLE; CATION EXCHANGE; CELL PROLIFERATION; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ION EXCHANGE CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDE MAPPING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR AFFINITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FILGRASTIM; MICE; PEPTIDE MAPPING; PROTEIN BINDING; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; SPECTRUM ANALYSIS;

EID: 78049515273     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11585100-000000000-00000     Document Type: Article

References (11)

1. Kelly C, Mir F. Economics of biological therapies. BMJ 2009; 339: b3276
2. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology 2006; 11: 341-6
3. Schellekens H. Biosimilar therapeutics: what do we need to consider? NDT Plus 2009; 2 Suppl. 1: i27-36
4. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Guideline on similar biological medicinal products [CHMP/437/04]. London: European Medicines Agency 2005 Oct 30 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/biosimilar/043704en. pdf [Accessed 2009 Oct 8]
5. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues [EMEA/CHMP/BWP/49348/2005]. London: European Medicines Agency, 2006 Feb 22 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/biosimilar/ 4934805en.pdf [Accessed 2009 Oct 8]
6. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor [EMEA/CHMP/BMWP/31329/2005]. London: European Medicines Agency, 2006 Feb 22 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/biosimilar/3132905en.pdf [Accessed 2009 Oct 8]
7. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22: 1383-91
8. Brockmeyer C, Seidl A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. EJHP Practice 2009; 15: 34-40
9. Filgrastim concentrated solution [monograph no. 07/2010:2206]. In: European Pharmacopoeia. 6th ed. Suppl. 6.8. Strasbourg: European Directorate for the Quality of Medicines & HealthCare (EDQM), 2010
10. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia "epidemic": mystery completely revealed? Perit Dial Int 2007; 27 Suppl. 2: S303-7
11. GasconP,Fuhr U,Sorgel F, etal. Development of anew G-CSF product based on biosimilarity assessment. Ann Oncol 2010 Jul; 21 (7): 1419-29